S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status:
Recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in
patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has
spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat
heart failure and high blood pressure, and it may prevent the heart from side effects of
chemotherapy.